Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 6.86
+0.10 (1.48%)
At close: Sep 30, 2026
Abera Bioscience AB Company Description
Abera Bioscience AB, a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally.
The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria.
Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis.
The company was incorporated in 2012 and is headquartered in Uppsala, Sweden.
Abera Bioscience AB
| Country | Sweden |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Maria Alriksson |
Contact Details
Address: Virdings allé 32 Uppsala, 754 50 Sweden | |
| Website | aberabio.com |
Stock Details
| Ticker Symbol | ABERA |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Maria Alriksson | Chief Executive Officer |
| Anders Ericsson | Executive Chairman of Board |
| Associate Prof. Joen Luirink | Co-Founder and Chief Technology Officer |
| Mats Lundgren | Vice President of Research and Development and CSO |